{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:03:31Z","timestamp":1790762611410,"version":"4.1.0"},"reference-count":51,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Biologic therapies are highly efficacious for pediatric atopic dermatitis (AD) and psoriasis (PsO); however, their expanding use has led to increased reports of phenotype switching\u2014a paradoxical condition where biologics induce new-onset immune-mediated dermatoses. To address clinical uncertainty regarding these complex reactions, this review evaluates real-world case reports, case series, and observational studies of pediatric AD and PsO patients who developed phenotypic switching during biologic therapy. Dupilumab is the most frequently implicated agent, commonly inducing psoriasiform, pustular, or palmoplantar eruptions in AD patients via a compensatory shift from Th2- to Th17-predominant immunity. Conversely, phenotype switching from IL-12\/23 and TNF-\u03b1 inhibitors remains rare in pediatric dermatology. For severe, refractory cases or AD-PsO overlaps, Janus kinase (JAK) inhibitors demonstrate significant rescue efficacy, provided appropriate baseline and ongoing laboratory monitoring is maintained. Pediatric patients experiencing biologic-induced phenotype switching can be successfully managed in clinical practice through early recognition and the implementation of the practical, evidence-based treatment algorithm proposed in this review.<\/jats:p>","DOI":"10.3390\/ijms27198740","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:25:42Z","timestamp":1790760342000},"page":"8740","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phenotype Switching in Pediatric Inflammatory Skin Diseases During Biologic Therapy: A Literature Review Focused on Atopic Dermatitis and Psoriasis"],"prefix":"10.3390","volume":"27","author":[{"given":"Chu-Fei","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Dermatology, Cathay General Hospital, Taipei City 106, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-5994","authenticated-orcid":false,"given":"Yu","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cathay General Hospital, Taipei City 106, Taiwan"},{"name":"Department of Dermatology, Sijhih Cathay General Hospital, New Taipei City 221037, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Miyagawa, F. (2022). Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071485"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Garcovich, S., De Simone, C., Genovese, G., Berti, E., Cugno, M., and Marzano, A.V. (2019). Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00282"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamadermatol.2023.0549","article-title":"Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor \u03b1 Inhibitors","volume":"159","author":"Eickstaedt","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/pde.14820","article-title":"Psoriasiform Dermatitis During Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Children","volume":"38","author":"Parker","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhang, Y., and Jiang, G. (2024). Application of JAK Inhibitors in Paradoxical Reaction Through Immune-Related Dermatoses. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1341632"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/pde.15497","article-title":"Dupilumab-Induced Psoriasiform Dermatitis in Two Pediatric Cardiac Transplant Patients","volume":"41","author":"Lockard","year":"2024","journal-title":"Pediatr. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/ds.DS-D-24-00197","article-title":"Janus Kinase of All Trades? Treatment of Ixekizumab- and Dupilumab-Related Paradoxical Reactions with Upadacitinib","volume":"44","author":"Tsai","year":"2025","journal-title":"Dermatol. Sin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2333016","DOI":"10.1080\/09546634.2024.2333016","article-title":"A Pediatric Case of Dupilumab-Induced Pustular Psoriasis","volume":"35","author":"Dang","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Trave, I., Salvi, I., Burlando, M., Cozzani, E., and Parodi, A. (2023). \u2018De Novo\u2019 Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196291"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ali, K., Wu, L., Qiu, Y., and Li, M. (2022). Clinical and Histopathological Characteristics of Psoriasiform Erythema and De Novo IL-17A Cytokine Expression in Atopic Dermatitis Children Treated with Dupilumab. Front. Med., 9.","DOI":"10.3389\/fmed.2022.932766"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/pde.70269","article-title":"Dupilumab-Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management with Abrocitinib","volume":"43","author":"Theodosiou","year":"2026","journal-title":"Pediatr. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/CCID.S420904","article-title":"Pustular Psoriasis in a Patient Treated with Dupilumab for Atopic Dermatitis: A Case Report","volume":"16","author":"Liu","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/DER.0000000000000824","article-title":"Dupilumab-Induced Palmoplantar Psoriasis: Is It True Psoriasis?","volume":"33","author":"Park","year":"2022","journal-title":"Dermatitis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2183729","DOI":"10.1080\/09546634.2023.2183729","article-title":"Upadacitinib for the Treatment of Concomitant Psoriasis and Atopic Dermatitis: A Case Series","volume":"34","author":"Gargiulo","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41590-018-0256-2","article-title":"The Epithelial Immune Microenvironment in Atopic Dermatitis and Psoriasis","volume":"19","author":"Dainichi","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical Eruptions to Targeted Therapies in Dermatology: A Systematic Review and Analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/imr.13230","article-title":"Engineering the IL-4\/IL-13 Axis for Targeted Immune Modulation","volume":"320","author":"Bernstein","year":"2023","journal-title":"Immunol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of Effector CD4 T Cell Populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual Blockade of IL-4 and IL-13 With Dupilumab, an IL-4R\u03b1 Antibody, Is Required to Broadly Inhibit Type 2 Inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1111\/all.70380","article-title":"Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4\/IL13 Genetics, and Response to IL4\/IL13 Blockade","volume":"81","author":"Hamilton","year":"2026","journal-title":"Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian Atopic Dermatitis Phenotype Combines Features of Atopic Dermatitis and Psoriasis with Increased TH17 Polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajhg.2014.12.004","article-title":"Genome-Wide Comparative Analysis of Atopic Dermatitis and Psoriasis Gives Insight into Opposing Genetic Mechanisms","volume":"96","author":"Baurecht","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tsai, Y.-C., and Tsai, T.-F. (2022). Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105518"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial Differences in Atopic Dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic Dermatitis and Psoriasis: Two Different Immune Diseases or One Spectrum?","volume":"48","author":"Krueger","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chen, C.H., Lee, M.S., Chang, W.Y., Cho, Y.T., Lu, Y.T., Huang, W.L., Chu, C.Y., Tsai, T.F., Krueger, J.G., and Chan, T.C. (2026). Uncovering a Dual T Helper 17\/Type 2 Transcriptomic Endotype in Psoriasis. J. Am. Acad. Dermatol., in press.","DOI":"10.1016\/j.jaad.2026.06.131"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","article-title":"Early-Onset Pediatric Atopic Dermatitis Is TH2 but Also TH17 Polarized in Skin","volume":"138","author":"Esaki","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41467-025-67665-w","article-title":"The E3 ligases Itch and WWP2 regulate autoimmune neuroinflammation by controlling TH2 to TH17 cell conversion via interleukin-4-STAT5 axis in mice","volume":"17","author":"Zhao","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e32844","DOI":"10.1097\/MD.0000000000032844","article-title":"Treatment of Paradoxical Eczematous Eruption in Psoriasis Treated with Secukinumab: A Case Report","volume":"102","author":"Xiao","year":"2023","journal-title":"Medicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40272-021-00440-8","article-title":"Paradoxical Psoriasis in Children Receiving Anti\u2013TNF\u03b1 Treatment for Inflammatory or Autoimmune Disease","volume":"23","author":"Rosenwasser","year":"2021","journal-title":"Pediatr. Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/pde.14712","article-title":"Paradoxical Psoriasis in Pediatric Patients: A Systematic Review","volume":"38","author":"Cyrenne","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14712598.2020.1727439","article-title":"Clinical and Histopathological Characterization of Eczematous Eruptions Occurring in the Course of Anti\u2013IL-17 Treatment: A Case Series and Review of the Literature","volume":"20","author":"Caldarola","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","article-title":"Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis","volume":"160","author":"Alabas","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2147\/CCID.S541725","article-title":"Successful Treatment of Ixekizumab-Induced Paradoxical Eczematous Reaction with JAK Inhibitors: A Case Report","volume":"18","author":"Fu","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic Switch to Eczema in Patients Receiving Biologics for Plaque Psoriasis: A Systematic Review","volume":"34","author":"Foulkes","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhao, D.J., Li, X., Lin, H.X., Zheng, H., Zhou, D., and Tang, P. (2024). Efficacy and Safety of Upadacitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis: A Systematic Review. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0306463"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2026.05.042","article-title":"A Distinct Psoriasis-Atopic Dermatitis Overlapping Phenotype in Adults With Dual Type 2 and Type 3 Immune Features and Favorable Response to Janus Kinase 1 Inhibition","volume":"95","author":"Chen","year":"2026","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of Care for the Management of Atopic Dermatitis in Adults With Phototherapy and Systemic Therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/pde.15721","article-title":"Analysis of Publicly Available Adverse Events Reported for Pediatric Patients Treated with Janus Kinase Inhibitors","volume":"41","author":"Talasila","year":"2024","journal-title":"Pediatr. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic Dermatitis","volume":"405","author":"Brunner","year":"2025","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of Baricitinib, Upadacitinib, and Tofacitinib Mediated Regulation of Cytokine Signaling in Human Leukocyte Subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic Dermatitis: An Expanding Therapeutic Pipeline for a Complex Disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/acr.25465","article-title":"Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 Trial","volume":"77","author":"Brunner","year":"2025","journal-title":"Arthritis Care Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhang, C., Fu, Z., Liu, J., Li, S., Chen, X., Zhang, Y., and Xie, J. (2025). Safety Profile and Dose-Dependent Adverse Events of Upadacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1598972"},{"key":"ref_46","unstructured":"AAAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu, D.K., Schneider, L., Asiniwasis, R.N., Boguniewicz, M., De Benedetto, A., Ellison, K., Frazier, W.T., Greenhawt, M., and Huynh, J. (2024). Atopic Dermatitis (Eczema) Guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-Based Recommendations. Ann. Allergy Asthma Immunol., 132, 274\u2013312."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ced\/llaf427","article-title":"Investigation of Infection Risk Associated with Janus Kinase Inhibitors: A Pharmacovigilance Analysis Using the Food and Drug Administration\u2019s Adverse Event Reporting System Database","volume":"51","year":"2026","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.clinthera.2024.07.003","article-title":"Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis","volume":"46","author":"Qian","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/pde.70297","article-title":"State-of-the-Art Review: Vaccination in Pediatric Dermatology Patients Receiving Immunosuppressive or Immunomodulatory Therapy: A Review","volume":"43","author":"Elaiho","year":"2026","journal-title":"Pediatr. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40272-023-00594-7","article-title":"Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward","volume":"25","author":"Bagri","year":"2023","journal-title":"Pediatr. Drugs"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8740\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:31:23Z","timestamp":1790760683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":51,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198740"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198740","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}